🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGLP-1 and beta-cell preservation — 12 month update Page 2

GLP-1 and beta-cell preservation — 12 month update

PeptideSynthNJ Sun, Dec 28, 2025 at 4:58 AM 7 replies 1,011 viewsPage 2 of 2
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Dec 28, 2025 at 6:09 AM#6
PeptideSynthNJ said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.7 (insulin resistant) → Current = 1.5 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

44 14tane_welly, Dr.PathRoch, mona_PHX and 41 others
Reply Quote Save Share Report
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Dec 28, 2025 at 6:37 AM#7

Following on from PedsEndoPhilly — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

43 13FranDenver, Dr.BariatricHTX, LindaRN_retired and 40 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Dec 28, 2025 at 7:05 AM#8
jason_paloalto said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 8 months: periods became regular for the first time in a decade, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my fertility specialist is optimistic about future conception.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

42 12BrianDallas92, labquiet_amy, emily_PDX and 39 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
Dec 28, 2025 at 7:33 AM#9
jason_paloalto said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 22 → 14 → 5 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

41 11MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 38 others
Reply Quote Save Share Report
MeganSA_TX
Member
634
2,890
Jun 2024
San Antonio, TX
Dec 28, 2025 at 9:45 AM#10
NurseAsh_DET said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

Last edited: Dec 28, 2025 at 11:45 AM
33 6mike.trainer_LA, sarah_nash92, FitDadDave and 30 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register